MEN1611 — Investigational Agent

PI3K Inhibitor · Phase 1/2 · Menarini Group

Mechanism of Action

MEN1611 is an oral class I PI3K inhibitor targeting the alpha, beta, and delta isoforms, blocking PI3K/AKT/mTOR signaling in PIK3CA-mutant tumors.

Investigational Indications

• PIK3CA-mutant HER2-positive metastatic breast cancer
• PIK3CA-mutant metastatic colorectal cancer

Key Trials